Table 1.
Clinical characteristic of study population
| Characteristic | RPS6K High(n = 58) |
RPS6K Low
(n = 89) |
P-value |
|---|---|---|---|
| Age | 0.784 | ||
| ≥ 50 | 43 | 69 | |
| < 50 | 15 | 20 | |
| Gender | 0.918 | ||
| Male | 50 | 76 | |
| Female | 8 | 13 | |
| Differentiation | 0.612 | ||
| Good | 27 | 46 | |
| Poor | 31 | 42 | |
| Tumor size | 0.020 | ||
| ≥ 5 cm | 36 | 72 | |
| < 5 cm | 22 | 17 | |
| Tumor number | 0.979 | ||
| Single | 41 | 64 | |
| Multiple | 17 | 25 | |
| Microvascular invasion | 0.292 | ||
| Yes | 24 | 46 | |
| No | 34 | 43 | |
| Macrovascular invasion | 0.996 | ||
| Yes | 20 | 32 | |
| No | 38 | 57 | |
| Lymph node metastasis | 0.067 | ||
| Yes | 0 | 3 | |
| No | 58 | 86 | |
| Cirrhosis | 0.098 | ||
| Yes | 46 | 58 | |
| No | 12 | 31 | |
| HBV infection | 0.623 | ||
| Yes | 38 | 63 | |
| No | 20 | 26 | |
| PLT | 150.5(99.25,188) | 165(124,219) | 0.030 |
| ALB | 39.85(35.325,42.475) | 42.5(38.7,44.9) | < 0.001 |
| ALT | 29.5(20,42.25) | 32(21,48) | 0.0643 |
| AST | 33(24,53) | 32(25,47) | 0.0704 |
| GGT | 64.5(35.25,104.75) | 83(47,163) | 0.042 |
| FBG | 4.875(4.4375,5.785) | 4.95(4.48,5.65) | 0.470 |
| TB | 14(10,18) | 14(11,16.5) | 0.047 |
| DB | 5(3,8.675) | 5(4,6) | 0.035 |
| IB | 8(6,10.075) | 9(7,10.2) | 0.180 |
| Serum AFP | 45.1(6.25,737.175) | 31.1(5.2,1905.9) | 0.176 |
| Serum CEA | 2.5(1.75,3.75) | 2.5(1.6,3.5) | 0.509 |
| Serum CA19-9 | 10(4.9,14.6) | 8.7(4.7,16) | 0.809 |
Continuous variables are expressed as mean ± standard deviation
Categorical variables given are the number of patients unless indicated otherwise
HBV Hepatitis B virus, PLT Platelet, ALB Albumin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, FBG Fasting blood glucose, TB Total bilirubin, DB Direct bilirubin, IB Indirect bilirubin, AFP α-fetoprotein, CEA Carcinoembryonic antigen, CA19-9 Carbohydrate antigen 19-9. The tumor size were calculated by chi-square method. PLT, ALB, GGT, TB and DB were calculated by Mann-Whitney U test